Month: September 2013
Roche executive says ultra-rare diseases outside core
By Ben Hirschler LONDON (Reuters) – Treating ultra-rare diseases is a distinct business from Roche's current area of expertise, the Swiss group's head of pharmaceuticals said, in comments that may cast doubt on its interest in Alexion Pharmaceuticals. "Our business is based on personalized healthcare and defining the patients most at risk and finding therapies," Daniel O'Day said in an interview during a visit to London this week. …
U.S. Republicans seek Obamacare delay for debt limit hike
By David Lawder WASHINGTON (Reuters) – Floating a strategy for thwarting “Obamacare” in autumn fiscal debates, House Republican leaders on Tuesday pledged to demand a one-year delay to the health reform law in any deal to raise the federal debt limit. They also unveiled a strategy to withhold money to implement Obamacare in connection with a stop-gap funding measure that would keep government agencies open from October 1 to December 15. …
'Power Foods for the Brain' author to speak Friday; part of University …
Chimerix’s viral drug fails to show improvement in mid-stage study
(Reuters) – Chimerix Inc said its experimental drug failed to show significant benefit in a mid-stage study involving a type of viral infection that mainly affects the lungs. The drug, brincidofovir, was being tested on 48 patients with blood and bone marrow cancers who had adenovirus infection (AdV), a potentially fatal condition which has no known approved treatments. The trial was designed to evaluate the potential to decrease the viral infection or prevent its progression. The drug was given to patients once or twice a week. …
Watch Tim Minchin's “Storm,” the Best Critique of Alternative …
Fact or Fiction: 12 Things to Know About Vaccines
Zen in the Art of Citizen Science: Apps for Collective Discovery and the 1 Percent Rule of the Web
Anxiety treatment options, fighting it the natural way
South Africa’s Aspen profit rises, it plans Russia campaign
JOHANNESBURG (Reuters) – South Africa’s Aspen Pharmacare said on Wednesday its full-year earnings rose by a quarter, helped by strong performance at home and overseas, and it was planning a push into Russia. Aspen, Africa’s largest maker of generic drugs, said diluted headline earnings totalled 786.9 cents per share, up from 626.9 cents a year earlier. Headline earnings, the main measure of profit in South Africa, exclude certain one-time items. Revenue rose by 27 percent to 19.3 billion rand. …
